Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue
Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.
You may also be interested in...
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).
The latest drug development news and highlights from our US FDA Performance Tracker.
Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.